

## CURRICULUM VITAE

Date of Revision: November 17, 2020  
Name: Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C)  
School: Yale School of Medicine

### Education:

BS, University of Alberta Biochemistry 1992  
MD, University of Alberta 1996  
MSc, University of Saskatchewan 2002  
MPH, Harvard School of Public Health 2007  
MA, University of Louisville 2009  
MBA, Yale University 2014

### Career/Academic Appointments:

1996 - 2002 General Surgery Residency, Surgery, University of Saskatchewan, Saskatoon, SK, Canada  
2002 - 2003 Interdisciplinary Breast Fellowship, Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX  
2010 - 2018 Associate Professor on Term, Oncology, Yale School of Medicine, New Haven, CT  
2018 - present Professor, Oncology, Yale School of Medicine, New Haven, CT

### Board Certification:

AB of Surgery, Surgery, General, 10-2004, 11-2012

### Professional Honors & Recognition:

#### International/National/Regional

2020 American Medical Association, Women Physicians Section, AMA Foundation, Joan F. Giambalvo Fund for the Advancement of Women  
2016 Clinical Research Forum, Distinguished Research Award  
2015 Breast Surgery International, Oral Presentation Prize  
2013 American College of Surgeons, Claude Organ MD, FACS Travelling Fellowship

#### Yale University

2015 Yale Cancer Center, Yale Cancer Center Clinical Research Award  
2015 Women Faculty Forum, Public Voices Thought Leadership Fellowship  
2015 Yale University Teaching and Learning Center, Horace W. Goldsmith Award  
2014 Yale University School of Management, Class Marshal  
2013 Yale University School of Management, Award for Excellence in Ethics and Leadership

## Grants/Clinical Trials History:

### Current Grants

Agency: American Medical Association/Joan Giambalvo Award  
I.D.#: Joan Giambalvo Award  
Title: Creation and assessment of a virtual negotiation workshop for women physicians  
Role: Principal Investigator  
Percent effort: N/A  
Direct costs per year: \$9,600.00  
Total costs for project period: \$9,600.00  
Project period: 10/1/2020

Agency: NIH  
I.D.#: NIH R01  
Title: A prospective, multi-center pivotal study of the LUM Imaging System for real-time, in vivo margin assessment in breast conserving surgery  
P.I.: Barbara Smith  
Role: Local PI  
Percent effort: N/A  
Direct costs per year: \$368,000.00  
Total costs for project period: \$368,000.00  
Project period: 9/1/2020

Agency: NIH  
I.D.#: NIH R01  
Title: A Randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherence  
P.I.: Sanft, Tara  
Role: Co-Investigator  
Percent effort: N/A  
Direct costs per year: \$3,280,907.00  
Total costs for project period: \$3,280,907.00  
Project period: 4/1/2017

Agency: NIH  
I.D.#: NIH  
Title: Lung Cancer SPORE  
P.I.: Herbst, Roy  
Role: Co-Director, Career Development Program

Percent effort: N/A  
Direct costs per year: \$7,395,190.00  
Total costs for project period: \$7,395,190.00  
Project period: 1/1/2015

### Current Clinical Trials

Agency: Lumicell, Inc.  
I.D.#: HIC# 2000023382  
Title: Feasibility Study Phase C: Expansion Into Multiple Institutions for Training in the Use of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer  
Role: Principal Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 12/7/2018

Agency: Alliance for Clinical Trials in Oncology  
I.D.#: HIC# 2000022800  
Title: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer  
P.I.: Mehra Golshan  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 8/13/2018

Agency: National Cancer Institute (NCI)  
I.D.#: HIC# 2000020335  
Title: Lifestyle, Exercise, and Nutrition Study Early after Diagnosis (LEANer)  
P.I.: Tara Sanft  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 3/1/2017

Agency: Yale Cancer Center  
I.D.#: HIC# 1602017205  
Title: A Multicenter Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients  
Role: Principal Investigator

Percent effort: N/A  
Total costs for project period: N/A  
Project period: 3/30/2016

Agency: Yale Cancer Center  
I.D.#: HIC# 1310012919  
Title: Prospective Collection of Tissue Specimens and Blood from Stage I-IV Breast Cancers for Molecular Analysis Repository  
P.I.: Tristen Park  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 12/4/2013

Agency: Alliance for Clinical Trials in Oncology  
I.D.#: HIC# 2000022933  
Title: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy  
P.I.: Mehra Golshan  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 6/24/2013

Agency: Beth Israel Deaconess Medical Center  
I.D.#: HIC# 1305012020  
Title: Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa  
P.I.: Kerin Adelson  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 6/14/2013

Agency: Terri Brodeur Breast Cancer Foundation  
I.D.#: HIC# 1302011482  
Title: Examination of Epigenetic Changes in Breast Tissue and Peripheral Blood of Women at Average versus Increased Risk of Breast Cancer  
P.I.: Erin Hofstatter  
Role: Sub-Investigator

Percent effort: N/A  
Total costs for project period: N/A  
Project period: 4/17/2013

Agency: Yale Cancer Center  
I.D.#: HIC# 1205010204  
Title: A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ  
P.I.: Erin Hofstatter  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 5/30/2012

Agency: Yale Cancer Center  
I.D.#: HIC# 1107008825  
Title: A Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients  
Role: Principal Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 9/14/2011

Agency: American Institute for Cancer Research  
I.D.#: HIC# 1012007780  
Title: Lifestyle, Exercise and Nutrition (LEAN) Study  
P.I.: Melinda Irwin  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 1/7/2011

#### Past Grants

Agency: NIH R01  
I.D.#: NIH R01  
Title: A prospective, multi-center pivotal study of the LUM Imaging System for real-time, in vivo margin assessment in breast conserving surgery  
P.I.: Barbara Smith  
Role: Local PI  
Percent effort: N/A

Direct costs per year: \$368,000.00  
Total costs for project period: \$368,000.00  
Project period: 10/1/2016 - 8/31/2020

Agency: NIH U10  
I.D.#: NIH U10  
Title: Yale Cancer Center NCTN  
P.I.: Howard Hochester  
Role: Co-Investigator  
Percent effort: N/A  
Direct costs per year: \$1,831,215.00  
Total costs for project period: \$1,831,215.00  
Project period: 7/1/2014 - 6/30/2019

Agency: AHRQ P30  
I.D.#: AHRQ P30  
Title: Yale Center for Healthcare Innovation, Redesign and Learning (CHIRAL)  
P.I.: Chaudhry, Sarwat  
Role: Collaborator  
Percent effort: N/A  
Direct costs per year: \$1,000,000.00  
Total costs for project period: \$1,000,000.00  
Project period: 1/1/2015 - 5/30/2019

Agency: Department of Defense, Era of Hope Award  
I.D.#: Department of Defense, Era of Hope Award  
Title: Molecular fingerprinting for targeting and eliminating breast cancers  
P.I.: Spiegel, David  
Role: Co-Investigator  
Percent effort: N/A  
Direct costs per year: \$3,896,563.00  
Total costs for project period: \$3,896,563.00  
Project period: 9/30/2013 - 9/29/2018

Agency: Connecticut Breast Health Initiative  
I.D.#: Connecticut Breast Health Initiative  
Title: SHAVE 2: A Multicenter Prospective Randomized Controlled Trial of Cavity Shave Margins vs. Standard Partial Mastectomy in Breast Cancer  
Role: Principal Investigator  
Percent effort: N/A

Direct costs per year: \$50,000.00  
Total costs for project period: \$50,000.00  
Project period: 9/1/2016 - 8/31/2018

Agency: NIH SBIR  
I.D.#: 1R44CA211013-01  
Title: A prospective, multi-center pivotal study of the LUM Imaging System for real-time, in vivo margin assessment in breast conserving surgery  
P.I.: Anees Chagpar  
Role: Local PI  
Percent effort: N/A  
Direct costs per year: \$1,970,214.00  
Total costs for project period: \$1,970,214.00  
Project period: 6/1/2016 - 5/31/2018

Agency: Foundation for Women's Wellness  
I.D.#: Foundation for Women's Wellness  
Title: Predicting occult multifocal breast cancer  
Role: Principal Investigator  
Percent effort: N/A  
Direct costs per year: \$25,000.00  
Total costs for project period: \$25,000.00  
Project period: 9/1/2015 - 12/31/2017

Agency: Breast Cancer Research Foundation (BCRF)  
I.D.#: Breast Cancer Research Foundation (BCRF)  
Title: Biological and biochemical effects of exercise and diet on breast tissue  
P.I.: Irwin, Melinda  
Role: Co-Investigator  
Percent effort: N/A  
Direct costs per year: \$250,000.00  
Total costs for project period: \$250,000.00  
Project period: 10/1/2015 - 9/30/2016

Agency: Susan G. Komen for the Cure  
I.D.#: 1108008892  
Title: PREHAB: Impact of physical activity on breast tissue biomarkers in women with early stage breast cancer  
P.I.: Irwin, Melinda  
Role: Co-Investigator

Percent effort: N/A  
Direct costs per year: \$1,000,000.00  
Total costs for project period: \$1,000,000.00  
Project period: 1/1/2011 - 12/31/2015

Agency: NIH/NINR  
I.D.#: NIH/NINR  
Title: Integrating Palliative Care into Self-Management of Breast Cancer  
P.I.: Dena Schulman-Green  
Role: Co-Investigator  
Percent effort: N/A  
Direct costs per year: \$287,380.00  
Total costs for project period: \$287,380.00  
Project period: 12/1/2013 - 11/30/2015

#### Past Clinical Trials

Agency: Icahn School of Medicine at Mount Sinai  
I.D.#: HIC# 1607018053  
Title: Insulin Resistance and Breast Cancer Prognosis in Black & White Women  
P.I.: Brigid Killelea  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 8/30/2016 - 6/21/2019

Agency: Yale Cancer Center  
I.D.#: HIC# 1304011944  
Title: Atypical Lesions of the Breast: Close Observation vs. Excision (ALCOVE)  
P.I.: Brigid Killelea  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 8/2/2013 - 6/21/2019

Agency: Yale Cancer Center  
I.D.#: HIC# 1110009173  
Title: A Pilot Study of Four-Dimensional Conformal Image Guided Accelerated Partial Breast Irradiation In the Treatment of Stage 0 and I Breast Carcinoma  
P.I.: Suzanne B. Evans  
Role: Sub-Investigator



Percent effort: N/A  
Total costs for project period: N/A  
Project period: 12/16/2011 - 11/19/2018

Agency: Yale University  
I.D.#: HIC# 1305012136  
Title: Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer  
P.I.: Lajos Pusztai  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 8/28/2013 - 8/3/2018

Agency: Yale Cancer Center  
I.D.#: HIC# 1605017696  
Title: Evaluation of Arm and Shoulder Function in Women diagnosed with Breast Cancer  
P.I.: Tish Knobf  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 5/16/2016 - 1/9/2018

Agency: National Institute of Nursing Research (NINR)  
I.D.#: HIC# 1307012400  
Title: Integrating Palliative Care Into Self-Management of Breast Cancer  
P.I.: Dena Schulman-Green  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 10/21/2013 - 9/27/2017

Agency: Genomic Health, Inc.  
I.D.#: HIC# 1312013177  
Title: Impact of the ONCOTYPE DX DCIS Score on Treatment Decision Making in Patients with Ductal Carcinoma in Situ  
Role: Principal Investigator  
Percent effort: N/A  
Total costs for project

period: N/A  
Project period: 6/5/2014 - 12/2/2015

Agency: Susan G. Komen Breast Cancer Foundation, Inc.  
I.D.#: HIC# 1108008892  
Title: The Preoperative Health and Body (PREHAB) Study  
P.I.: Melinda Irwin  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project  
period: N/A  
Project period: 1/6/2012 - 12/1/2015

Agency: Rhode Island Hospital  
I.D.#: HIC# 0705002672  
Title: Q3week Carboplatin with Weekly Abraxane and Trastuzumab as Neoadjuvant  
Therapy in Resectable and Unresectable HER2+ (stage IIA-IIIC) Breast Cancer  
P.I.: Maysa Abu-Khalaf  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project  
period: N/A  
Project period: 9/10/2007 - 10/27/2015

Agency: Yale University School of Medicine  
I.D.#: HIC# 1004006675  
Title: Evaluation and Treatment of Subclinical Lymphedema in Patients Undergoing  
Treatment for Breast Cancer  
P.I.: Susan A. Higgins  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project  
period: N/A  
Project period: 7/28/2010 - 8/11/2015

Agency: Yale University School of Medicine  
I.D.#: HIC# 1505015922EXEMPT  
Title: Variations in practice in breast cancer management  
Role: Principal Investigator  
Percent effort: N/A  
Total costs for project  
period: N/A  
Project period: 6/11/2015 - 6/11/2015

Agency: Faxitron Bioptics, LLC  
I.D.#: HIC# 1304011815  
Title: Intra-Operative Specimen Imaging in Breast Cancer Patients Undergoing Standard Partial Mastectomy: A Pilot of the Faxitron BioVision Wedge 3D versus BioVision 2D Imaging  
Role: Principal Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 4/24/2013 - 3/4/2015

Agency: National Institute on Drug Abuse (NIDA)  
I.D.#: HIC# 1104008332  
Title: Novel Treatments to Enhance Smoking Cessation before Cancer Surgery: Effects on Smoking and Surgical Outcomes  
P.I.: Benjamin Toll  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 5/11/2011 - 4/30/2014

Agency: American Cancer Society  
I.D.#: HIC# 1102008055  
Title: Delivery of a Survivorship Care Plan to Breast Cancer Patients, a Feasibility Study  
P.I.: Tara Sanft  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 4/4/2011 - 3/19/2014

Agency: Yale Cancer Center  
I.D.#: HIC# 1210010924  
Title: Modeling Human Immune System Interaction with Breast Tumors and Treatments in Mice  
P.I.: Alfred Bothwell  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period: N/A  
Project period: 11/30/2012 - 2/26/2014

Agency: Yale Cancer Center  
I.D.#: HIC# 1207010483  
Title: Assessment of Breast Cancer Intratumor Heterogeneity Using Next Generation Sequencing and Correlation of Clonal Diversity with Clinical Phenotype  
Role: Principal Investigator  
Percent effort: N/A  
Total costs for project period:  
period: N/A  
Project period: 7/24/2012 - 2/26/2014

### Pending Clinical Trials

Agency: Alliance Foundation Trials, LLC  
I.D.#: HIC# 2000025675  
Title: COMPARISON OF OPERATIVE TO MONITORING AND ENDOCRINE THERAPY (COMET) TRIAL FOR LOW RISK DCIS: A PHASE III PROSPECTIVE RANDOMIZED TRIAL  
P.I.: Brigid Killelea  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period:  
period: N/A  
Project period: 3/12/2020

Agency: NRG Oncology Foundation, Inc.  
I.D.#: HIC# 2000024691  
Title: A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer  
P.I.: Tristen Park  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period:  
period: N/A  
Project period: 9/16/2019

Agency: National Institute of Nursing Research (NINR)  
I.D.#: HIC# 2000021044  
Title: A Palliative Care Intervention for Patient-Family Caregiver Dyads Managing Advanced Cancer  
P.I.: Dena Schulman-Green  
Role: Sub-Investigator  
Percent effort: N/A  
Total costs for project period:  
period: N/A

Project period: 8/1/2017

Agency: Lumicell, Inc.  
I.D.#: HIC# 2000026847  
Title: PIVOTAL STUDY OF THE LUM IMAGING SYSTEM FOR ASSISTING  
INTRAOPERATIVE DETECTION OF RESIDUAL CANCER IN THE TUMOR BED OF  
FEMALE PATIENTS WITH BREAST CANCER  
Role: Principal Investigator  
Percent effort: N/A  
Total costs for project  
period: N/A

### Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale: International/National

- 2019: Doctors Hospital at Renaissance, Edinburg, TX. ""Genetics and its Impact on Breast Cancer Treatment""
- 2019: Doctors Hospital at Renaissance, Edinburg, TX. ""Skin-sparing and Nipple-sparing Mastectomy""
- 2019: Sister Caritas Cancer Center/Mercy Medical Center, Springfield, MA. ""Management of the Axilla in the Setting of Neoadjuvant Therapy""
- 2019: University of Toronto, Toronto, ON, Canada. ""Do positive margins always need re-excision?""
- 2019: Miami Breast Cancer Symposium, Miami, FL. ""Physician Burnout: An Action-Oriented Roundtable Discussion""
- 2019: Miami Breast Cancer Symposium, Miami, FL. ""Is Marking of Axillary Nodes Necessary?""
- 2019: Miami Breast Cancer Symposium, Miami, FL. ""Update on Margins""
- 2019: Doctors Hospital at Renaissance, Edinburg, TX. ""Lessons learned from the SHAVE2 trial""
- 2019: Doctors Hospital at Renaissance, Edinburg, TX. ""Surgical Considerations in the Setting of Neoadjuvant Therapy""
- 2018: American College of Surgeons Clinical Congress, Boston, MA. ""History and Trends of Contralateral Prophylactic Mastectomy""; Session on ""Are we doing too many bilateral mastectomies""
- 2018: University of Kansas School of Medicine, Wichita, KS. ""Improving margin clearance: Lessons learned from the SHAVE trial(s)""
- 2018: American Society of Breast Surgeons Annual Meeting, Orlando, FL. ""Debate: Should re-excision rates be a quality measure?: Pro""
- 2018: American Association of Cancer Research, Chicago, IL. ""How to Negotiate a Job Offer""
- 2018: Association of American Medical Colleges, Seattle, WA. ""Bouncing Up or Burning Out? Tools to improve individual and Institutional Resilience""
- 2018: Miami Breast Cancer Symposium, Miami, FL. ""Surgery of the Primary Tumor in the Metastatic Setting""
- 2018: Miami Breast Cancer Symposium, Miami, FL. ""Is Surgical Excision/Radiation Required for Low-Grade, Low-Recurrence-Score DCIS?""
- 2018: Miami Breast Cancer Symposium, Miami, FL. ""Mammography/Accelerated Breast MRI: Great Screening or Overdiagnosis?""

- 2017: American College of Surgeons Clinical Congress, San Diego, CA. ""Socioeconomic status and financial toxicity: another lens into disparities""
- 2017: 20th Brazilian Congress of Mastology, Porto de Galinhas, PE, Brazil. ""Does the Shave Play a Role in Oncoplastic Surgery""
- 2017: 20th Brazilian Congress of Mastology, Porto de Galinhas, PE, Brazil. ""What Can We do to Reduce Reopening Surgery?""
- 2017: 20th Brazilian Congress of Mastology, Porto de Galinhas, PE, Brazil. ""Breast Cancer in Elderly Women. What is the Best Surgical Treatment?""
- 2017: 20th Brazilian Congress of Mastology, Porto de Galinhas, PE, Brazil. ""Surgery in Metastatic Patients. When to Recommend?""
- 2017: Seattle Cancer Alliance, Seattle, WA. ""DCIS Management: Cancer or not? -- Surgery and radiation: YES""
- 2017: University of Illinois Medical School, Peoria, IL. ""Contralateral Risk Reducing Mastectomy: Pros and Cons""
- 2017: Midwestern/Central Surgical Association Meeting, Chicago, IL. ""On Baseball and Breast Cancer""
- 2017: Association of American Medical Colleges, Fajardo, Fajardo, Puerto Rico. ""Bouncing Up or Burning Out? Tools to Improve Individual and Institutional Resilience""
- 2017: National Consortium of Breast Cancers Annual Meeting, Las Vegas, NV. ""Surgery of the Axilla Post-Z-0011: When to complete an axillary dissection, and how to manage the axilla after neoadjuvant therapy""
- 2017: Miami Breast Cancer Symposium, Miami, FL. ""Current Approaches to Triple-Negative Breast Cancer""
- 2017: Miami Breast Cancer Symposium, Miami, FL. ""Surgical Approach to Margins in Invasive Breast Cancer SHAVE 1 and SHAVE 2 Trials""
- 2017: Miami Breast Cancer Symposium, Miami, FL. ""How MACRA will affect Breast Cancer Practice""
- 2017: Ohio State University, Columbus, OH. ""Harnessing Your Personal Leadership""
- 2017: Boston University/Boston Medical Center,, Boston, MA. ""The Future of Academic Surgery: My View of the Universe""
- 2017: Huntsman Cancer Institute/University of Utah, Salt Lake City, UT. ""Lessons Learned from the SHAVE trial""
- 2016: Association of American Medical Colleges, Austin, TX. ""Negotiation 101: How to Grow the Pie and Get Your Fair Share""
- 2016: Western Surgical Annual Meeting, Coronado, CA. ""Triple Negative Breast Cancer: Light through the Darkness""
- 2016: Japanese Society for Clinical Oncology Annual Congress, Yokohama, Kanagawa, Japan. ""Recent Advances in Breast Cancer Management: the U.S. Perspective""
- 2016: North York General Hospital, Toronto, ON, Canada. ""Management of the Axilla Post-Neoadjuvant Chemotherapy""
- 2016: University of Saskatchewan, Saskatoon, SK, Canada. ""Masters of Surgery and Beyond""
- 2016: University of Alberta, Edmonton, AB, Canada. ""The Future of Academic Surgery: Challenges and Opportunities""
- 2016: Trinidad and Tobago Surgical Skills Workshop, Port of Spain, Port of Spain Corporation, Trinidad and Tobago. ""Role of Surgery in Breast Cancer Genetics""

- 2016: National Conference on Next Generation Comprehensive Breast Centers of Excellence, Jacksonville, FL. ""From Good to Great: Yale's journey to become the first NCI-designated cancer center with an internationally accredited breast center""
- 2016: Goiania Breast Cancer Symposium, Goiânia, GO, Brazil. ""Results of the SHAVE Trial""
- 2016: Goiania Breast Cancer Symposium, Goiânia, GO, Brazil. ""What should be considered a free margin? The Surgeon's Standpoint""
- 2016: Goiania Breast Cancer Symposium, Goiânia, GO, Brazil. ""When should we consider surgery in the setting of metastatic disease?""
- 2016: Global Breast Cancer Conference, Jeju-si, Jeju-do, South Korea. ""Cavity Shave Margins: Method and Impact on Practice""
- 2016: American Society of Breast Surgeons, Dallas, TX. ""Surgical considerations in mutation carriers""
- 2016: National Consortium of Breast Centers/American Society of Breast Diseases, Las Vegas, NV. ""Cost-Effective Care of the Breast Cancer Patient: How the Disciplines Can Work Together to Reduce Unnecessary Evaluations and Interventions While Preserving Quality""
- 2016: National Consortium of Breast Centers/American Society of Breast Diseases, Las Vegas, NV. ""Do Margins Matter?""
- 2016: National Consortium of Breast Centers/American Society of Breast Diseases, Las Vegas, NV. ""The Best of the National Meetings: Everything I Need to Know I Learned at NCBC""
- 2016: Miami Breast Cancer Symposium, Miami, FL. ""Contralateral Risk Reducing Mastectomy: Pros and Cons""
- 2016: Miami Breast Cancer Symposium, Miami, FL. ""Routine Shave Margins vs. Standard Partial Mastectomy""
- 2016: Miami Breast Cancer Symposium, Miami, FL. ""Multisite Disease and Breast Conservation""
- 2015: Tata Memorial Hospital, Mumbai, MH, India. ""Cancer 101""
- 2015: Institute of Cytology & Preventive Oncology, New Delhi, DL, India. ""Dialogue Between a Journalist and A Researcher""
- 2015: NCI Cancer Research in the Media in India, Mumbai, MH, India. ""Reporting on research findings""
- 2015: Living Beyond Breast Cancer, Denver, CO. ""Inflammatory Breast Cancer: The Latest Treatment Approaches""
- 2015: International Congress on Future of Breast Cancer, Huntington Beach, CA. ""Contralateral Prophylactic Mastectomy""
- 2015: Georgia Regents University, Augusta, GA. ""Doing well by doing good: towards a vision of value in cancer care""
- 2015: John Wayne Cancer Institute, Santa Monica, CA. ""Transforming Breast Cancer Care: From Science to Systems""
- 2014: SIS World Congress on Breast Healthcare, Orlando, FL. ""Is there an International Consensus on the Treatment of Axillary Lymph Nodes?""
- 2014: SIS World Congress on Breast Healthcare, Orlando, FL. ""Atypical Lesions of the Breast: Selection Criteria for Surgery""
- 2014: SIS World Congress on Breast Healthcare, Orlando, FL. ""Optimal axillary management with positive sentinel lymph nodes""

- 2014: SIS World Congress on Breast Healthcare, Orlando, FL. "Meet the Expert- Surgical Management of BRCA Carriers"
- 2013: School of Breast Oncology, Atlanta, GA. ""The Role of Sentinel Node Biopsy and Axillary Dissection""
- 2013: The University of Texas MD Anderson Cancer Center, Houston, TX. ""Sentinel Lymph Node Biopsy in Breast Cancer: Evolution and Revolution""
- 2013: Dana-Farber Cancer Center, Boston, MA. ""Sentinel Lymph Node Biopsy in Breast Cancer: Evolution and Revolution""
- 2013: Massachusetts General Hospital, Boston, MA. ""Addressing Diversity in Breast Cancer Patients""
- 2013: Southwestern Surgical Congress, Santa Barbara, CA. ""Debate: MRI in Breast Cancer: Friend or Foe?""
- 2013: Miami Breast Cancer Symposium, Miami, FL. ""The need for repeat biopsy after recurrence""
- 2013: Miami Breast Cancer Symposium, Miami, FL. ""Sentinel Node Biopsy After Pre-operative Therapy""
- 2013: Miami Breast Cancer Symposium, Miami, FL. ""What patients can/cannot do after axillary surgery""
- 2013: Miami Breast Cancer Symposium, Miami, FL. ""Is There Value to Local Control in Selected Patients With Stage IV Disease""
- 2013: Multidisciplinary Symposium on Breast Disease, Amelia City, FL. ""Building Blocks for the Multidisciplinary Breast Center: Lessons Learned from the NAPBC""
- 2012: University College London Cancer Center, London, England, United Kingdom. ""And now for something different...addressing heterogeneity in cancers and communities""
- 2011: American Society of Breast Diseases, Washington, DC. ""Is Breast Surgery a Money-Losing Enterprise?""
- 2011: Southwestern Surgical Congress, Southwestern Surgical Congress, Honolulu, HI. ""Innovation in Surgery: From imagination to implementation""
- 2011: Marmara University Hospital, İstanbul, İstanbul, Turkey. ""Clinical Significance of Minimal Sentinel Node Involvement and Management Options""
- 2011: University of Acibadem, İstanbul, İstanbul, Turkey. ""Timing and Accuracy of Sentinel Node Biopsy in Patients Receiving Neoadjuvant Chemotherapy""
- 2011: University of Acibadem, İstanbul, İstanbul, Turkey. ""Controversial Technical and Clinical Issues in Sentinel Node Biopsy in Breast Cancer""
- 2011: University of Acibadem, İstanbul, İstanbul, Turkey. ""Multidisciplinary Management of Breast Cancer: the Elements of an Ideal Breast Center""

## Regional

- 2019: Greenwich Hospital Breast Center Educational Day, Greenwich, CT. ""Breast Cancer Disparities""
- 2019: Women's Medical Association of Fairfield County, Fairfield, CT. ""What's New in Breast Cancer Management""
- 2018: Continuing Medical Education on Breast Cancer, Hartford, CT. ""Surgical Aspect of Breast Cancer""



- 2016: Valley Hospital Blumenthal Cancer Center, Ridgewood, NJ. ""Medical, Surgical and Radiographic Management of High Risk Breast Lesions""
- 2016: Upstate Medical University, Syracuse, NY. ""The Promise and Perils of Neoadjuvant Therapy in the Management of Breast Cancer""
- 2016: Community Health Network Foundation, New Haven, CT. ""Recent Advances in Breast Cancer Management: How close are we to finding a cure?""
- 2015: National Association of Cancer Center Development Officers and the Public Affairs Network Conference, New Haven, CT. ""Cancer 101""
- 2015: Yale New Haven Hospital, New Haven, CT. ""Surgical Management of Lymph Nodes in Patients with Breast Cancer""

## Bibliography:

### Peer-Reviewed Original Research

1. Karmy-Jones R, **Chagpar A**, Vallieres E, Hamilton S. Colobronchial fistula due to Crohn's disease. *The Annals Of Thoracic Surgery* 1995, 60:446-8.
2. **Chagpar A**. Chronic fatigue syndrome: a prodrome to psychosis? *Canadian Journal Of Psychiatry. Revue Canadienne De Psychiatrie* 1996, 41:536-7.
3. **Chagpar A**, Carter JW. Lymphoma presenting as a Sister Mary Joseph's nodule. *The American Surgeon* 1998, 64:799-800.
4. **Chagpar A**, Moyana TN, Chappell EW. Isolated metachronous jejunal metastases after resection of bronchogenic carcinoma. *Canadian Journal Of Surgery. Journal Canadien De Chirurgie* 2000, 43:57-8.
5. **Chagpar A**, Kanthan SC. Vaginal metastasis of colon cancer. *The American Surgeon* 2001, 67:171-2.
6. **Chagpar A**, Meric-Bernstam F, Hunt KK, Ross MI, Cristofanilli M, Singletary SE, Buchholz TA, Ames FC, Marcy S, Babiera GV, Feig BW, Hortobagyi GN, Kuerer HM. Chest wall recurrence after mastectomy does not always portend a dismal outcome. *Annals Of Surgical Oncology* 2003, 10:628-34.
7. **Chagpar A**, Kuerer HM, Hunt KK, Strom EA, Buchholz TA. Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. *International Journal Of Radiation Oncology, Biology, Physics* 2003, 57:128-35.
8. **Chagpar A**, Yen T, Sahin A, Hunt KK, Whitman GJ, Ames FC, Ross MI, Meric-Bernstam F, Babiera GV, Singletary SE, Kuerer HM. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. *American Journal Of Surgery* 2003, 186:371-7.
9. **Chagpar AB**, Martin RC, Hagendoorn LJ, Chao C, McMasters KM. Lumpectomy margins are affected by tumor size and histologic subtype but not by biopsy technique. *American Journal Of Surgery* 2004, 188:399-402.
10. **Chagpar AB**. Advances in the management of localized breast cancer: an overview. *The Journal Of The Kentucky Medical Association* 2004, 102:202-8.
11. **Chagpar AB**. Skin-sparing and nipple-sparing mastectomy: preoperative, intraoperative, and postoperative considerations. *The American Surgeon* 2004, 70:425-32.
12. **Chagpar AB**, McMasters KM. Sentinel lymph node biopsy for breast cancer: from investigational procedure to standard practice. *Expert Review Of Anticancer Therapy* 2004, 4:903-12.

13. **Chagpar A**, Martin RC, Chao C, Wong SL, Edwards MJ, Tuttle T, McMasters KM. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. *Archives Of Surgery (Chicago, Ill. : 1960)* 2004, 139:614-8; discussion 618-20.
14. **Chagpar A**, Eveleigh M, Fritsche HA, Krishnamurthy S, Hunt KK, Kuerer HM. Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase-Schiff reaction in ductal fluid samples from women with breast carcinoma. *Cancer* 2004, 100:2549-54.
15. **Chagpar A**, Langstein HN, Kronowitz SJ, Singletary SE, Ross MI, Buchholz TA, Hunt KK, Kuerer HM. Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction. *American Journal Of Surgery* 2004, 187:164-9.
16. **Chagpar A**, Magliocco A, Kerviche A, Tan L, Walley B, DeCoteau JF. The replication error phenotype is associated with the development of distant metastases in hormonally treated patients with breast carcinoma. *Cancer* 2004, 100:913-9.
17. **Chagpar AB**, Scoggins CR, Sahoo S, Martin RC, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, Noyes RD, Ley PB, Tuttle TM, McMasters KM. Biopsy type does not influence sentinel lymph node status. *American Journal Of Surgery* 2005, 190:551-6.
18. **Chagpar AB**, Kehdy F, Scoggins CR, Martin RC, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, Noyes RD, Ley PB, Tuttle TM, McMasters KM. Effect of lymphoscintigraphy drainage patterns on sentinel lymph node biopsy in patients with breast cancer. *American Journal Of Surgery* 2005, 190:557-62.
19. Hutchinson JR, **Chagpar AB**, Scoggins CR, Martin RC, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, Noyes RD, Ley PB, Tuttle TM, McMasters KM. Surgeon and community factors affecting breast cancer sentinel lymph node biopsy. *American Journal Of Surgery* 2005, 190:903-6.
20. **Chagpar AB**, Martin RC, Scoggins CR, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, Noyes RD, Ley PB, Tuttle TM, McMasters KM. Factors predicting failure to identify a sentinel lymph node in breast cancer. *Surgery* 2005, 138:56-63.
21. **Chagpar A**, Middleton LP, Sahin AA, Meric-Bernstam F, Kuerer HM, Feig BW, Ross MI, Ames FC, Singletary SE, Buchholz TA, Valero V, Hunt KK. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. *Cancer* 2005, 103:1581-6.
22. Martin RC, **Chagpar A**, Scoggins CR, Edwards MJ, Hagendoorn L, Stromberg AJ, McMasters KM. Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. *Annals Of Surgery* 2005, 241:1005-12; discussion 1012-5.
23. Scoggins CR, **Chagpar AB**, Martin RC, McMasters KM. Should sentinel lymph-node biopsy be used routinely for staging melanoma and breast cancers? *Nature Clinical Practice. Oncology* 2005, 2:448-55.
24. Alatassi H, Pile NS, **Chagpar AB**, Sahoo S. Breast biopsy marker masquerading as a mass lesion. *The Breast Journal* 2005, 11:504-5.
25. **Chagpar AB**, Scoggins CR, Martin RC, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, McMasters KM. Prediction of sentinel lymph node-only disease in women with invasive breast cancer. *American Journal Of Surgery* 2006, 192:882-7.
26. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Edwards MJ, **Chagpar AB**, Martin RC, Stromberg AJ, Hagendoorn L, McMasters KM. Gender-related differences in outcome for melanoma patients. *Annals Of Surgery* 2006, 243:693-8; discussion 698-700.

27. **Chagpar AB**, Studts JL, Scoggins CR, Martin RC, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, Noyes RD, McMasters KM. Factors associated with surgical options for breast carcinoma. *Cancer* 2006, 106:1462-6.
28. **Chagpar AB**, McMasters KM, Martin RC, Thoene C, Nurko JY, Edwards MJ. Determinants of early distant metastatic disease in elderly patients with breast cancer. *American Journal Of Surgery* 2006, 192:317-21.
29. **Chagpar AB**, McMasters KM. Treatment of sentinel node-positive breast cancer. *Expert Review Of Anticancer Therapy* 2006, 6:1233-9.
30. Tafta L, Fine R, Whitworth P, Berry M, Woods J, Ekblom G, Gass J, Beitsch P, Dodge D, Han L, Potruch T, Francescatti D, Oetting L, Smith JS, Snider H, Kleban D, **Chagpar A**, Akbari S. Prospective randomized study comparing cryo-assisted and needle-wire localization of ultrasound-visible breast tumors. *American Journal Of Surgery* 2006, 192:462-70.
31. **Chagpar AB**. Predicting extensive nodal disease in women with breast cancer. *Annals Of Surgical Oncology* 2006, 13:3-4.
32. **Chagpar AB**, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. *Annals Of Surgery* 2006, 243:257-64.
33. **Chagpar AB**, Scoggins CR, Martin RC, Cook EF, McCurry T, Mizuguchi N, Paris KJ, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, McMasters KM. Predicting patients at low probability of requiring postmastectomy radiation therapy. *Annals Of Surgical Oncology* 2007, 14:670-7.
34. **Chagpar AB**, McMasters KM. Trends in mammography and clinical breast examination: a population-based study. *The Journal Of Surgical Research* 2007, 140:214-9.
35. **Chagpar AB**, Scoggins CR, Martin RC, Sahoo S, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, McMasters KM. Factors determining adequacy of axillary node dissection in breast cancer patients. *The Breast Journal* 2007, 13:233-7.
36. **Chagpar AB**, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, Noyes RD, Ley PB, Tuttle TM, McMasters KM. Factors influencing the number of sentinel lymph nodes identified in patients with breast cancer. *American Journal Of Surgery* 2007, 194:860-4; discussion 864-5.
37. **Chagpar AB**. Insights into the management of locally advanced, inflammatory, and metastatic breast cancer: highlights from the 2007 Louisville Breast Cancer Update. *The Journal Of The Kentucky Medical Association* 2007, 105:559-60.
38. **Chagpar AB**, McMasters KM, Saul J, Nurko J, Martin RC, Scoggins CR, Edwards MJ. Body mass index influences palpability but not stage of breast cancer at diagnosis. *The American Surgeon* 2007, 73:555-60; discussion 560.
39. Blumencranz P, Whitworth PW, Deck K, Rosenberg A, Reintgen D, Beitsch P, **Chagpar A**, Julian T, Saha S, Mamounas E, Giuliano A, Simmons R. Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. *American Journal Of Surgery* 2007, 194:426-32.
40. Sahoo S, Sanders MA, Roland L, Pile N, **Chagpar AB**. A strategic approach to the evaluation of axillary lymph nodes in breast cancer patients: analysis of 168 patients at a single institution. *American Journal Of Surgery* 2007, 194:524-6.
41. **Chagpar AB**, Heim K, Carron KR, Sewell C. Extramammary Paget's disease of the axilla: an unusual case. *The Breast Journal* 2007, 13:291-3.

42. **Chagpar AB**, Scoggins CR, Martin RC, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, McMasters KM. Are 3 sentinel nodes sufficient? *Archives Of Surgery (Chicago, Ill. : 1960)* 2007, 142:456-9; discussion 459-60.
43. Sahoo S, Talwalkar SS, Martin AW, **Chagpar AB**. Pathologic evaluation of cryoprobe-assisted lumpectomy for breast cancer. *American Journal Of Clinical Pathology* 2007, 128:239-44.
44. Sahoo S, Alatassi H, Bernstein M, Slone SP, **Chagpar AB**. Breast carcinoma metastatic to ameloblastoma: a unique tumour-to-tumour metastasis. *Histopathology* 2007, 50:815-7.
45. Federico AC, **Chagpar AB**, Ross MI, Martin RC, Noyes RD, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, McMasters KM, Scoggins CR. Effect of multiple-nodal basin drainage on cutaneous melanoma. *Archives Of Surgery (Chicago, Ill. : 1960)* 2008, 143:632-7; discussion 637-8.
46. **Chagpar AB**, Polk HC, McMasters KM. Racial trends in mammography rates: a population-based study. *Surgery* 2008, 144:467-72.
47. Julian TB, Blumencranz P, Deck K, Whitworth P, Berry DA, Berry SM, Rosenberg A, **Chagpar AB**, Reintgen D, Beitsch P, Simmons R, Saha S, Mamounas EP, Giuliano A. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. *Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology* 2008, 26:3338-45.
48. **Chagpar AB**, McMasters KM, Scoggins CR, Martin RC, Thoene C, Edwards MJ. The use of radiation therapy after breast-conserving surgery in hormonally treated breast cancer patients is dependent on patient age, geographic region, and surgeon specialty. *American Journal Of Surgery* 2008, 195:793-8.
49. Slomiany BA, McMasters KM, **Chagpar AB**. The recent decline in mammography rates is limited to low- to average-risk women. *American Journal Of Surgery* 2008, 196:821-6; discussion 826.
50. **Chagpar AB**. Highlights from the Louisville breast cancer update. An update on the management of high-risk breast cancer and preinvasive disease. *The Journal Of The Kentucky Medical Association* 2008, 106:537-8.
51. **Chagpar AB**, McMasters KM, Sahoo S, Edwards MJ. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis? *Surgery* 2009, 146:561-7; discussion 567-8.
52. **Chagpar AB**, McMasters KM, Edwards MJ. Can sentinel node biopsy be avoided in some elderly breast cancer patients? *Annals Of Surgery* 2009, 249:455-60.
53. Slomiany BA, **Chagpar AB**. The surgical management of breast cancer. *The Journal Of The Kentucky Medical Association* 2009, 107:391-5.
54. Nasser SM, Smith SG, **Chagpar AB**. The role of sentinel node biopsy in women undergoing prophylactic mastectomy. *The Journal Of Surgical Research* 2010, 164:188-92.
55. Reuter NP, Bower M, Scoggins CR, Martin RC, McMasters KM, **Chagpar AB**. The lower incidence of melanoma in women may be related to increased preventative behaviors. *American Journal Of Surgery* 2010, 200:765-8, discussion 768-9.
56. **Chagpar AB**. Clinical significance of minimal sentinel node involvement and management options. *Surgical Oncology Clinics Of North America* 2010, 19:493-505.
57. Schiffman SC, **Chagpar AB**. Does a family history of male breast cancer influence risk perception and use of genetic testing? *The American Surgeon* 2010, 76:879-82.
58. Smith SG, **Chagpar AB**. Adherence to physical activity guidelines in breast cancer survivors. *The American Surgeon* 2010, 76:962-5.

59. Lewis JD, **Chagpar AB**, Shaughnessy EA, Nurko J, McMasters K, Edwards MJ. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. *Cancer* 2010, 116:2307-15.
60. Blaker KM, Sahoo S, Schweichler MR, **Chagpar AB**. Malignant phylloides tumor in pregnancy. *The American Surgeon* 2010, 76:302-5.
61. Patel JD, Galsky MD, **Chagpar AB**, Pyle D, Loehrer PJ. Role of American Society of Clinical Oncology in low- and middle-income countries. *Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology* 2011, 29:3097-102.
62. **Chagpar AB**, McMasters KM. Comparing prediction models: the distinction between clinical and statistical significance. *Annals Of Surgical Oncology* 2011, 18 Suppl 3:S265.
63. **Chagpar AB**. Edgar J. Poth Memorial Lecture. Innovation in surgery: from imagination to implementation. *American Journal Of Surgery* 2011, 202:641-5.
64. **Chagpar AB**, Crutcher CR, Cornwell LB, McMasters KM. Primary tumor size, not race, determines outcomes in women with hormone-responsive breast cancer. *Surgery* 2011, 150:796-801.
65. Schiffman SC, McMasters KM, Scoggins CR, Martin RC, **Chagpar AB**. Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients. *Journal Of The American College Of Surgeons* 2011, 213:45-52; discussion 52-3.
66. Cornwell LB, McMasters KM, **Chagpar AB**. The impact of lymphovascular invasion on lymph node status in patients with breast cancer. *The American Surgeon* 2011, 77:874-7.
67. **Chagpar AB**, Camp RL, Rimm DL. Lymph node ratio should be considered for incorporation into staging for breast cancer. *Annals Of Surgical Oncology* 2011, 18:3143-8.
68. Dedert E, Lush E, **Chagpar A**, Dhabhar FS, Segerstrom SC, Spiegel D, Dayyat E, Daup M, McMasters K, Sephton SE. Stress, coping, and circadian disruption among women awaiting breast cancer surgery. *Annals Of Behavioral Medicine : A Publication Of The Society Of Behavioral Medicine* 2012, 44:10-20.
69. Lannin DR, Killelea B, Horowitz N, **Chagpar AB**. Validation of the Louisville breast sentinel node prediction models and a proposed modification to guide management of the node positive axilla. *The American Surgeon* 2012, 78:761-5.
70. Evans SB, Yu JB, **Chagpar A**. How radiation oncologists would disclose errors: results of a survey of radiation oncologists and trainees. *International Journal Of Radiation Oncology, Biology, Physics* 2012, 84:e131-7.
71. Sue GR, Lannin DR, Killelea B, **Chagpar AB**. Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. *American Journal Of Surgery* 2013, 206:478-81.
72. Sue GR, Lannin DR, Killelea B, Tsangaris T, **Chagpar AB**. Does time to definitive treatment matter in patients with ductal carcinoma in situ? *The American Surgeon* 2013, 79:561-5.
73. Killelea BK, Lannin DR, Horvath LJ, Horowitz NR, **Chagpar AB**. Factors associated with breast MRI use: a population-based analysis. *Annals Of Surgical Oncology* 2013, 20:1798-805.
74. Killelea BK, Long JB, **Chagpar AB**, Ma X, Soulos PR, Ross JS, Gross CP. Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. *Breast Cancer Research And Treatment* 2013, 141:155-63.
75. Gross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, Gold HT, **Chagpar AB**, Ma X. The cost of breast cancer screening in the Medicare population. *JAMA Internal Medicine* 2013, 173:220-6.

76. Sue GR, Lannin DR, Au AF, Narayan D, **Chagpar AB**. Factors associated with decision to pursue mastectomy and breast reconstruction for treatment of ductal carcinoma in situ of the breast. *American Journal Of Surgery* 2013, 206:682-5.
77. Killelea BK, **Chagpar AB**, Bishop J, Horowitz NR, Christy C, Tsangaris T, Raghu M, Lannin DR. Is there a correlation between breast cancer molecular subtype using receptors as surrogates and mammographic appearance? *Annals Of Surgical Oncology* 2013, 20:3247-53.
78. Bonito A, Horowitz N, McCorkle R, **Chagpar AB**. Do healthcare professionals discuss the emotional impact of cancer with patients? *Psycho-oncology* 2013, 22:2046-50.
79. Bishop JD, Killelea BK, **Chagpar AB**, Horowitz NR, Lannin DR. Smoking and breast cancer recurrence after breast conservation therapy. *International Journal Of Breast Cancer* 2014, 2014:327081.
80. Wiznia LE, Lannin DR, Evans SB, Hofstatter EW, Horowitz NR, Killelea BK, Tsangaris TN, **Chagpar AB**. The number of lymph nodes dissected in breast cancer patients influences the accuracy of prognosis. *Annals Of Surgical Oncology* 2014, 21:389-94.
81. Rutter CE, **Chagpar AB**, Evans SB. Breast cancer laterality does not influence survival in a large modern cohort: implications for radiation-related cardiac mortality. *International Journal Of Radiation Oncology, Biology, Physics* 2014, 90:329-34.
82. **Chagpar AB**. Prophylactic bilateral mastectomy and contralateral prophylactic mastectomy. *Surgical Oncology Clinics Of North America* 2014, 23:423-30.
83. Greer LT, Rosman M, Charles Mylander W, Liang W, Buras RR, **Chagpar AB**, Edwards MJ, Tafra L. A prediction model for the presence of axillary lymph node involvement in women with invasive breast cancer: a focus on older women. *The Breast Journal* 2014, 20:147-53.
84. **Chagpar AB**. Claude H. Organ, Jr., MD, FACS, traveling fellow reports on experience in India. *Bulletin Of The American College Of Surgeons* 2014, 99:76-9.
85. Knobf MT, Major-Campos M, **Chagpar A**, Seigerman A, McCorkle R. Promoting quality breast cancer care: psychosocial distress screening. *Palliative & Supportive Care* 2014, 12:75-80.
86. Tewari A, **Chagpar AB**. Worry about breast cancer recurrence: a population-based analysis. *The American Surgeon* 2014, 80:640-5.
87. Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, **Chagpar AB**, Gross CP. Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer. *Journal Of The National Cancer Institute* 2014, 106:dju008.
88. Killelea BK, Long JB, **Chagpar AB**, Ma X, Wang R, Ross JS, Gross CP. Evolution of breast cancer screening in the Medicare population: clinical and economic implications. *Journal Of The National Cancer Institute* 2014, 106.
89. Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR, Abu-Khalaf M, Horowitz NR, **Chagpar AB**. Impact of financial burden of cancer on survivors' quality of life. *Journal Of Oncology Practice / American Society Of Clinical Oncology* 2014, 10:332-8.
90. Kanumuri P, Hayse B, Killelea BK, **Chagpar AB**, Horowitz NR, Lannin DR. Characteristics of Multifocal and Multicentric Breast Cancers. *Annals Of Surgical Oncology* 2015, 22:2475-82.
91. Onibokun O, Killelea BK, **Chagpar AB**, Horowitz NR, Lannin DR. The left sided predominance of breast cancer is decreasing. *The Breast Journal* 2015, 21:213-5.
92. Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, **Chagpar AB**, Lannin DR. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. *Journal Of The American College Of Surgeons* 2015, 220:1063-9.

93. **Chagpar AB**, Butler M, Killelea BK, Horowitz NR, Stavris K, Lannin DR. Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients? A prospective cohort study. *American Journal Of Surgery* 2015, 210:886-90.
94. **Chagpar AB**. Cavity Shave Margins in Breast Cancer. *The New England Journal Of Medicine* 2015, 373:2187-8.
95. Feinstein AJ, Long J, Soulos PR, Ma X, Herrin J, Frick KD, **Chagpar AB**, Krumholz HM, Yu JB, Ross JS, Gross CP. Older women with localized breast cancer: costs and survival rates increased across two time periods. *Health Affairs (Project Hope)* 2015, 34:592-600.
96. Bulloch KJ, Irwin ML, **Chagpar AB**, Puztai L, Killelea BK, Horowitz NR, Hofstatter EW, Abu-Khalaf MM, DiGiovanna M, Chung GG, Sanft TB. Systematic approach to providing breast cancer survivors with survivorship care plans: a feasibility study. *Journal Of Oncology Practice / American Society Of Clinical Oncology* 2015, 11:e170-6.
97. **Chagpar A**, Babiera G, Aguirre J, Caropreso P, Hughes T. Variation in metastatic workup for patients with invasive breast cancer. *American Journal Of Surgery* 2015, 210:1147-54.e2; discussion 1153-4.
98. Sue GR, **Chagpar AB**. Predictors of recurrence in patients diagnosed with ductal carcinoma in situ. *The American Surgeon* 2015, 81:48-51.
99. Callender GG, Kaplan BJ, White RL, Brenin DR, **Chagpar AB**, Dalal KM, Howard-McNatt M, Howe J, Kim J, Kurtzman SH, Mansour JC, Mittendorf EA, Stewart JH, Temple LK, Stella P, Cummings C, Wong SL, Klimberg VS. Maintenance of certification: what everyone needs to know. *Annals Of Surgical Oncology* 2015, 22:1051-4.
100. Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, Sanft TB, Puztai L, Gross CP, **Chagpar AB**. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. *Cancer* 2015, 121:2544-52.
101. Cash E, Sephton SE, **Chagpar AB**, Spiegel D, Rebholz WN, Zimmaro LA, Tillie JM, Dhabhar FS. Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery. *Brain, Behavior, And Immunity* 2015, 48:102-14.
102. Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, **Chagpar AB**, Puztai L, Lannin DR. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. *Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology* 2015, 33:4267-76.
103. **Chagpar AB**, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Puztai L, Horowitz NR. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. *The New England Journal Of Medicine* 2015, 373:503-10.
104. Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, **Chagpar AB**, Puztai L, Rimm DL. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. *Breast Cancer Research : BCR* 2016, 18:78.
105. James TA, Coffman AR, **Chagpar AB**, Boughey JC, Klimberg VS, Morrow M, Giuliano AE, Harlow SP. Troubleshooting Sentinel Lymph Node Biopsy in Breast Cancer Surgery. *Annals Of Surgical Oncology* 2016, 23:3459-3466.
106. Harrigan M, Cartmel B, Loftfield E, Sanft T, **Chagpar AB**, Zhou Y, Playdon M, Li F, Irwin ML. Randomized Trial Comparing Telephone Versus In-Person Weight Loss Counseling on Body Composition and Circulating Biomarkers in Women Treated for Breast Cancer: The Lifestyle, Exercise, and Nutrition (LEAN) Study. *Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology* 2016, 34:669-76.

107. Hayse B, Hooley RJ, Killelea BK, Horowitz NR, **Chagpar AB**, Lannin DR. Breast cancer biology varies by method of detection and may contribute to overdiagnosis. *Surgery* 2016, 160:454-62.
108. Ramaswamy AT, Toll B, **Chagpar AB**, Judson BL. Reply to smoking cessation for patients with cancer: "The Emperor's New Clothes". *Cancer* 2016, 122:2926.
109. Ramaswamy AT, Toll BA, **Chagpar AB**, Judson BL. Smoking, cessation, and cessation counseling in patients with cancer: A population-based analysis. *Cancer* 2016, 122:1247-53.
110. Sledge GW, **Chagpar A**, Perou C. Collective Wisdom: Lobular Carcinoma of the Breast. *American Society Of Clinical Oncology Educational Book / ASCO. American Society Of Clinical Oncology Meeting* 2016, 35:18-21.
111. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, **Chagpar AB**, Lannin DR. Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. *Medicine* 2016, 95:e4614.
112. Howard DH, Soulos PR, **Chagpar AB**, Mougalian S, Killelea B, Gross CP. Contrary To Conventional Wisdom, Physicians Abandoned A Breast Cancer Treatment After A Trial Concluded It Was Ineffective. *Health Affairs (Project Hope)* 2016, 35:1309-15.
113. Hanna J, Lannin D, Killelea B, Horowitz N, **Chagpar AB**. Factors Associated with Persistently Positive Margin Status after Breast-Conserving Surgery in Women with Breast Cancer: An Analysis of the National Cancer Database. *The American Surgeon* 2016, 82:748-52.
114. Schulman-Green D, Linsky S, Jeon S, Kapo J, Blatt L, **Chagpar A**. Integrating palliative care into self-management of breast cancer: Protocol for a pilot randomized controlled trial. *Contemporary Clinical Trials* 2016, 48:133-8.
115. Wiznia L, Dai F, **Chagpar AB**. Do non-melanoma skin cancer survivors use tanning beds less often than the general public? *Dermatology Online Journal* 2016, 22.
116. Jain AK, Fennell ML, **Chagpar AB**, Connolly HK, Nembhard IM. Moving Toward Improved Teamwork in Cancer Care: The Role of Psychological Safety in Team Communication. *Journal Of Oncology Practice / American Society Of Clinical Oncology* 2016, 12:1000-1011.
117. **Chagpar AB**, Babiera GV, Aguirre J, Hunt KK, Hughes T. Variation in Practice of the Diagnostic Workup of Asymptomatic Patients Diagnosed with Invasive Breast Cancer. *Frontiers In Oncology* 2016, 6:56.
118. **Chagpar AB**, Hughes T, Hunt K, Aguirre J, Babiera G. Variation in Follow-up of Asymptomatic Breast Cancer Patients: Can We Choose More Wisely? *The American Surgeon* 2016, 82:e188-90.
119. Rutter CE, Yao X, Mancini BR, Aminawung JA, **Chagpar AB**, Saglam O, Hofstatter EW, Abu-Khalaf M, Gross CP, Evans SB. Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer. *Clinical Breast Cancer* 2016, 16:59-62.
120. Thomas P, Killelea BK, Horowitz N, **Chagpar AB**, Lannin DR. Racial Differences in Utilization of Breast Conservation Surgery: Results from the National Cancer Data Base (NCDB). *Annals Of Surgical Oncology* 2016, 23:3272-83.
121. Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, **Chagpar AB**, Pusztai L. Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. *Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research* 2016, 22:26-33.
122. Killelea BK, **Chagpar AB**, Horowitz NR, Lannin DR. Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011. *American Journal Of Surgery* 2017, 213:426-432.



123. Tasoulis MK, Hughes T, Babiera G, **Chagpar AB**. Sentinel lymph node biopsy in low risk settings. *American Journal Of Surgery* 2017, 214:489-494.
124. Dzimitrowicz H, Mougalian S, Storms S, Hurd S, **Chagpar AB**, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. *Journal Of Oncology Practice / American Society Of Clinical Oncology* 2017, 13:e1012-e1020.
125. **Chagpar AB**, Cicek AF, Harigopal M. Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients? *The American Surgeon* 2017, 83:704-708.
126. Ndarukwa S, Nyakabau AM, **Chagpar AB**, Raben D, Ndlovu N, Kadzatsa W, Eaton VJ, Mafunda P, Razis E. American Society of Clinical Oncology Multidisciplinary Cancer Management Course: Connecting Lives, Cancer Care, Education, and Compassion in Zimbabwe-A Pilot for Efforts of Sustainable Benefit? *Journal Of Global Oncology* 2017, 3:409-417.
127. Chiu AS, Thomas P, Killelea BK, Horowitz N, **Chagpar AB**, Lannin DR. Regional variation in breast cancer surgery: Results from the National Cancer Database (NCDB). *American Journal Of Surgery* 2017, 214:907-913.
128. **Chagpar AB**, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP. Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled Trial. *Annals Of Surgery* 2017, 265:39-44.
129. von Wahlde MK, Timms KM, **Chagpar AB**, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid JE, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pusztai L. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer. *Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research* 2017, 23:1193-1199.
130. Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, **Chagpar A**, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J. Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. *Annals Of Surgical Oncology* 2017, 24:660-668.
131. Hunt KK, Euhus DM, Boughey JC, **Chagpar AB**, Feldman SM, Hansen NM, Kulkarni SA, McCreedy DR, Mamounas EP, Wilke LG, Van Zee KJ, Morrow M. Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. *Annals Of Surgical Oncology* 2017, 24:375-397.
132. **Chagpar AB**, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR. Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer? *American Journal Of Surgery* 2017, 214:1082-1088.
133. Berrocal J, Saperstein L, Grube B, Horowitz NR, **Chagpar AB**, Killelea BK, Lannin DR. Intraoperative Injection of Technetium-99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution Experience. *Surgery Research And Practice* 2017, 2017:5924802.
134. **Chagpar AB**, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70

- Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. *Annals Of Surgical Oncology* 2017, 24:3073-3081.
135. **Chagpar AB**, Tsangaris TN, Lannin DR. Do All Positive Margins in Breast Cancer Patients Undergoing a Partial Mastectomy Need to Be Resected? *Journal Of The American College Of Surgeons* 2018, 227:13-21.
  136. Levinsohn E, Altman M, **Chagpar AB**. Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ. *The American Surgeon* 2018, 84:1-6.
  137. Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, **Chagpar A**, Horowitz N, Frederick C, Rispoli L, Burrello T, Abu-Khalaf M, Sabbath K, Sanft T, Brandt DS, Hofstatter EW, Hatzis C, DiGiovanna MP, Pusztai L. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. *Breast Cancer Research And Treatment* 2018, 169:333-340.
  138. Rebholz WN, Cash E, Zimmaro LA, Bayley-Veloso R, Phillips K, Siwik C, **Chagpar AB**, Dhabhar FS, Spiegel D, Bell BS, Sephton SE. Distress and quality of life in an ethnically diverse sample awaiting breast cancer surgery. *Journal Of Health Psychology* 2018, 23:1438-1451.
  139. **Chagpar AB**. On baseball and breast cancer. *American Journal Of Surgery* 2018, 215:353-356.
  140. **Chagpar AB**, Wilke LG. Should Reexcision Rates in Breast Cancer Care be a Quality Measure? *Annals Of Surgical Oncology* 2018, 25:2818-2822.
  141. Huang J, **Chagpar AB**. Quality of Life and Body Image as a Function of Time from Mastectomy. *Annals Of Surgical Oncology* 2018, 25:3044-3051.
  142. Sanft T, Usiskin I, Harrigan M, Cartmel B, Lu L, Li FY, Zhou Y, **Chagpar A**, Ferrucci LM, Pusztai L, Irwin ML. Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. *Breast Cancer Research And Treatment* 2018, 172:105-112.
  143. Huang J, **Chagpar A**. Complications in patients with unilateral breast cancer who undergo contralateral prophylactic mastectomy versus unilateral mastectomy. *Surgery* 2018, 164:1347-1350.
  144. Huang J, **Chagpar A**. Impact of anticipated financial burden on patient decision to undergo contralateral prophylactic mastectomy. *Surgery* 2018, 164:856-865.
  145. **Chagpar AB**. How I treat breast cancer with positive lymph nodes. *Clinical Advances In Hematology & Oncology : H&O* 2018, 16:486-490.
  146. Hofstatter EW, Horvath S, Dalela D, Gupta P, **Chagpar AB**, Wali VB, Bossuyt V, Storniolo AM, Hatzis C, Patwardhan G, Von Wahlde MK, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L. Increased epigenetic age in normal breast tissue from luminal breast cancer patients. *Clinical Epigenetics* 2018, 10:112.
  147. Wilson PC, **Chagpar AB**, Cicek AF, Bossuyt V, Buza N, Mougalian S, Killelea BK, Patel N, Harigopal M. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score. *The Breast Journal* 2018, 24:976-980.
  148. Shi W, Ng CKY, Lim RS, Jiang T, Kumar S, Li X, Wali VB, Piscuoglio S, Gerstein MB, **Chagpar AB**, Weigelt B, Pusztai L, Reis-Filho JS, Hatzis C. Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. *Cell Reports* 2018, 25:1446-1457.
  149. Huang J, **Chagpar A**. Does the Day of the Week a Mastectomy Is Performed Influence Length of Stay? *The American Surgeon* 2018, 84:e228-e230.

150. Huang J, **Chagpar AB**. Reply: Complications in unilateral breast cancer patients who undergo contralateral prophylactic mastectomy versus unilateral mastectomy. *Surgery* 2019, 165:486-496.
151. Huang J, **Chagpar A**. Factors associated with decision to undergo contralateral prophylactic mastectomy versus unilateral mastectomy. *American Journal Of Surgery* 2019, 218:170-174.
152. Rahimy E, Weidhaas J, Wei W, Lannin D, Horowitz N, Higgins S, Wilson LD, Knowlton C, Moran MS, Young MR, Killelea B, **Chagpar A**, Yeboa DN, Zelterman D, Evans S. Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation. *Practical Radiation Oncology* 2019, 9:e257-e265.
153. **Chagpar AB**. Defining Why the Re-excision Rate Dropped. *Annals Of Surgical Oncology* 2019, 26:1176-1177.
154. Zeeshan S, Ali B, Ahmad K, **Chagpar AB**, Sattar AK. Clinicopathological Features of Young Versus Older Patients With Breast Cancer at a Single Pakistani Institution and a Comparison With a National US Database. *Journal Of Global Oncology* 2019, 5:1-6.
155. Ligibel J, Dillon DA, Giobbie-Hurder A, McTiernan A, Frank ES, Cornwell M, Pun M, Campbell N, Dowling RJO, Chang MC, Tolaney SM, **Chagpar AB**, Yung R, Freedman RA, Dominici LS, Golshan M, Rhei E, Taneja K, Huang Y, Brown M, Winer EP, Jeselsohn R, Irwin ML. Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study. *Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research* 2019, 25:5398-5406.
156. Trant AA, Szekely B, Mougalian SS, DiGiovanna MP, Sanft T, Hofstatter E, Silber A, Adelson KB, **Chagpar A**, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L. The impact of communication style on patient satisfaction. *Breast Cancer Research And Treatment* 2019, 176:349-356.
157. Huang J, **Chagpar A**. Active Participation in Decision-Making in Contralateral Prophylactic Mastectomy for Patients With Breast Cancer. *The Journal Of Surgical Research* 2019, 242:129-135.
158. Dupont E, Tsangaris T, Garcia-Cantu C, Howard-McNatt M, Chiba A, Berger AC, Levine EA, Gass JS, Gallagher K, Lum SS, Martinez RD, Willis AI, Pandya SV, Brown EA, Fenton A, Mendiola A, Murray M, Solomon NL, Senthil M, Ollila DW, Edmonson D, Lazar M, Namm JP, Li F, Butler M, McGowan NE, Herrera ME, Avitan YP, Yoder B, Walters LL, McPartland T, **Chagpar AB**. Resection of Cavity Shave Margins in Stage 0-III Breast Cancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial. *Annals Of Surgery* 2019.
159. Wang M, Huang J, **Chagpar AB**. Can I Keep My Nipple? Factors Influencing the Surgical Decision between Skin-Sparing and Nipple-Sparing Mastectomy. *The American Surgeon* 2019, 85:768-771.
160. Wang M, Huang J, **Chagpar AB**. Is nipple sparing mastectomy associated with increased complications, readmission and length of stay compared to skin sparing mastectomy? *American Journal Of Surgery* 2020, 219:1030-1035.
161. Huang J, **Chagpar A**. Effect of decision-making resources on satisfaction with decision to undergo contralateral prophylactic mastectomy (CPM). *American Journal Of Surgery* 2020, 219:1036-1038.
162. Huang J, Wang M, **Chagpar A**. Factors Associated with Reconstruction in Patients Undergoing Mastectomy. *The American Surgeon* 2020, 86:134-139.
163. Wang M, Huang J, **Chagpar AB**. Do Obese Patients Present With More Advanced Breast Cancer? *The American Surgeon* 2020, 3134820949510.

164. Ginter PS, Idress R, D'Alfonso TM, Fineberg S, Jaffer S, Sattar AK, **Chagpar A**, Wilson P, Harigopal M. Histologic grading of breast carcinoma: a multi-institution study of interobserver variation using virtual microscopy. *Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc* 2020.

#### Invited Editorials and Commentaries

165. **Chagpar A**, Kuerer HM., *Women's Oncology Review* 2003; 3: 174-175.
166. **Chagpar AB.**, *Breast Diseases: A Yearbook Quarterly* 2003; 14: 154.
167. **Chagpar AB.**, *Breast Diseases: A Year Book Quarterly* 2004; 15: 281.
168. **Chagpar AB.** Commentary on: Preoperative estimation of the pathological breast tumor size by physical examination, mammography and ultrasound: A prospective study on 105 invasive tumors [Eur J Radiol 48:285-292, 2003]. *Breast Diseases: A Year Book Quarterly* 2004; 15: 251
169. **Chagpar AB.** Commentary on: Breast cancer with chest wall progression: Treatment with photodynamic therapy [Ann Surg Oncol 11:322-327, 2004]. *Breast Diseases: A Year Book Quarterly* 2004; 15: 299.
170. **Chagpar AB.** Commentary on: Measurement of tumour size in case selection for breast cancer therapy by clinical assessment and ultrasound [Eur J Surg Oncol 30:5-9, 2004]. *Breast Diseases: A Year Book Quarterly* 2005; 15: 415.
171. **Chagpar AB.** Commentary on: Influence of breast cancer histology on the relationship between ultrasound and pathology measurements [Mod Pathol 17:905-910, 2004]. *Breast Diseases: A Year Book Quarterly* 2005; 16: 48-49.
172. **Chagpar AB.** Commentary on: Use of preoperative breast ultrasonography for mapping of breast cancer extent improves resection margins during breast conservation surgery [Arch Surg 139:863-869, 2004]. *Breast Diseases: A Year Book Quarterly* 2005; 16: 55.
173. **Chagpar AB.** Commentary on: Pathologic nipple discharge: Surgery is imperative in postmenopausal women [Ann Surg Oncol 12:546-551, 2005] *Breast Diseases: A Yearbook Quarterly* 2006; 17:1.
174. **Chagpar AB.** Editorial on: Lymphoscintigraphy and sentinel lymph node biopsy of the internal mammary nodes: Is it worth it? [American Journal of Surgery 190: 557-562, 2005] *Breast Diseases: A Year Book Quarterly* 2006; 17: 1.
175. **Chagpar AB.** Commentary on: Full-Thickness chest wall resection for recurrence of breast malignancy [The Breast Journal, 11(4): 273-277, 2005] *Breast Diseases: A Year Book Quarterly* 2006; 17: 2.
176. **Chagpar AB.** Commentary on: Sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy. [Ann Surg Oncol 13(8): 1099-104, 2006] *Breast Diseases: A Year Book Quarterly* 2007; 18:2.
177. **Chagpar AB.** Commentary on: Risk factors for non-sentinel lymph node metastases in patients with breast cancer: the outcome of a multi-institutional study [Ann Surg Oncol, 14(1)181-189, 2007] *Breast Diseases: A Year Book Quarterly* 2007; 18: 3.
178. **Chagpar AB.** Commentary on: A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. [Ann Surg 245(3): 462-468, 2007] *Breast Diseases: A Year Book Quarterly* 2007; 18: 4.
179. **Chagpar AB, McMasters KM, Scoggins CR.** Editorial on: The use of radiation therapy after breast-conserving surgery in hormonally treated breast cancer patients is dependent on patient age,

- geographic region, and surgeon specialty” [Am J Surg 195:793-798, 2008] Breast Diseases: A Year Book Quarterly 2009; 19: 4.
180. **Chagpar AB.** Commentary on: How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? [Cancer 113(1): 30-37, 2008] Breast Diseases: A Year Book Quarterly 2009; 20: 1.
  181. **Chagpar AB.** Commentary on: Is the “10% rule” equally valid for all subsets of sentinel-node-positive breast cancer patients? [Ann Surg 15(10):728-2733, 2008] Breast Diseases: A Year Book Quarterly 2009; 20: 1.
  182. **Chagpar AB.** Commentary on: Optimal number of radioactive sentinel lymph nodes to remove for accurate axillary staging of breast cancer [Surgery 144:525-32, 2008] Breast Diseases: A Year Book Quarterly 2009; 20: 2.
  183. **Chagpar AB, Polk HC, McMasters, KM.** Editorial on: Racial trends in mammography rates: A population-based study” [Surgery 144:467-472, 2008] Breast Diseases: A Year Book Quarterly 2009; 20: 2.
  184. **Chagpar AB.** Commentary on: Preoperative axillary staging in breast cancer – Saving time and resources [The Breast Journal 14(4):369-371, 2008] Breast Diseases: A Year Book Quarterly, 2010; 20: 4.
  185. **Chagpar AB.** Commentary on: Prognostic factors in 77 curative chest wall resections for isolated breast cancer recurrence [Ann Surg Oncol 16:3414-3421, 2009] Breast Diseases: A Year Book Quarterly, 2010, 21: 2.
  186. **Chagpar AB.** Commentary on: Accuracy of sentinel lymph node biopsy in large and multifocal/multicentric breast carcinoma – a systematic review [Eur J Surg Oncol 37:371-385, 2011] Breast Diseases: A Year Book Quarterly, 2012, 23(1).
  187. **Chagpar AB.** “Diversity: The Color in the Tapestry of Human Experience”; Case In Point 2012; 10(8): 13.
  188. **Chagpar AB, Galsky M, Patel J.** “Responding to the Global Cancer Crisis through Innovation, Leadership”, ASCO Daily News Expert Editorial, 2013.
  189. **Chagpar AB.** Commentary on: A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes [Eur J Surg Oncol. 40(7):835-42, 2014] Breast Diseases: A Year Book Quarterly”, 2014.
  190. **Chagpar AB.** “Surgical margins and minimizing the need for re-excision”, Breast Diseases: A Year Book Quarterly, 2016, Vol 27, No 3, June 2016.
  191. **Chagpar AB.** “Studies review updates in mammography, mastectomy and margin width”, Hematology Oncology Today, June 10, 2016, pp. 1-2.
  192. **Chagpar AB.** “Masters of Surgery and Beyond”, in Festschrift in honor of Dr. Roger Keith, Canadian Journal of Surgery 2016; 60(1):6-7.
  193. **Chagpar AB.** Commentary on: Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: A Report of a Randomized Prospective Study in a Public Hospital [Annals of Surgical Oncology (2016) 23:456-464]: Breast Diseases: A Year Book Quarterly, 2017, 27(4): 297.
  194. **Chagpar AB.** Commentary on: Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing a Prophylactic Mastectomy: A Systematic Review and Meta-Analysis [Breast J (2016) 22:158-165]: Breast Diseases: A Year Book Quarterly, 2017, 27(4): 284.

195. **Chagpar AB**, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Puztai L, Lannin DR. Discussion of: "Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?" *American Journal Of Surgery* 2017, 214:1089-1090.

**Case Reports, Technical Notes, Letters**

196. Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, **Chagpar AB**, Gross CP. Response. *Journal Of The National Cancer Institute* 2014, 106.